🔴 Current Evidence on Tricuspid Regurgitation Interventions in Heart Failure @JACCJournals #Cardiology #cardioEd

Truncating LMNA variants lead to worse arrhythmic outcomes regardless of position, whereas missense variants in the tail domain, particularly in exons 7 to 12, are associated with better cardiac outcomes. https://t.co/tqYs4I4ceF

1 year data on aficamten in the FOREST HCM trial are now published in JACC Journals https://t.co/iFjzRnJsrj #CardioTwitter

Join us tomorrow for the #HFA_ESC webinar: "Heart Failure in the Community" 📌 3 June 2025 | 18.00-19.00 CET 🎙️Faculty: @ARakisheva, @Kieranfdocherty, @m4ggiesimpson, @KlausKWitte 🔗 Register now: https://t.co/OnvjTj3yF7 @escardio

Age-specific troponin thresholds: considerations for the fifth universal definition of myocardial infarction in EHJ. https://t.co/GrxYPXRZV4 @ESCardio @ESC_Journals #age #5UDMI @johnwmcevoy

🚨 New HFA/ESC consensus statement! 🚨 Clinical management & therapy optimization for HFrEF patients with low BP—practical guidance for safer, more effective treatment. 📄👇 #HeartFailure https://t.co/bHKiwMfbcp @AmrAbdin10 @GiuseppeGalati_ @HanCardiomd @HSkouri @EJHFEiC #EJHF

📌Standardized Definitions of Changes in Kidney Function in Trials of #HeartFailure: @JACCJournals Expert Panel From the #HFARC #CardioRenal #ClinicalTrials #HF #CKD

Torsemide is proposed to have clinically important pharmacokinetic and pharmacodynamic advantages over furosemide. This study found no meaningful pharmacokinetic/pharmacodynamic advantages for torsemide versus furosemide. https://t.co/uvXjwFQnVk @ClevelandClinic @CleClinicMD

🗞️ SUGAR-DM-HF #CMR estimated PCWP & congestion markers, and effect of #empagliflozin in #HFrEF with dysglycaemia @ESC_Journals @GiuseppeGalati_ @AmrAbdin10 @HanCardiomd @HFA_President https://t.co/0zUDx2TPsp

EMPRESS-MI: Empagliflozin vs placebo, n=105 w/ LVSD (mean LVEF 34.8%) post-AMI (24wks): ↔️LVESVI, LVEDVI, LVEF, LAVI, LVMI ↔️NT-proBNP, hs-TnI ↗️Hct ↘️urate, weight 🔗 https://t.co/y9H63nVVB0 @CarberryJaclyn @Kieranfdocherty @markcpetrie20 @ColinBerryMD @UoGHeartFailure @UofGSCMH

Final clap for #CVCT2024 ! Thank you for 3 days of deep scientific discussions, inspiration and friendship ! Now, time for action ! #clinicaltrials #movingforward

Cardiovascular trials still under-represent diverse groups relative to population disease distribution. In @NatureMedicine, @OtavioBerwanger, @hvanspall, and @FaiezZANNAD share insights on making clinical trials in this field more inclusive. Read more: https://t.co/nM0grT9YUs

It's a wrap up for the Day 1 of #CVCT2024 ! Brilliant discussions, friendships and moving the needle in clinical trials ! #CVCT #clinicaltrials #clinicalresearch

Great discussions with great colleagues on current and future challenges of real world evidence, including pragmatic trials @CVCTForum #CVCT2024

Our latest paper summarising evidence for subcutaneous furosemide in heart failure.

Register now for the 2025 @HFHubScotland annual Ensuring success with #HeartFailure conference Register here https://t.co/QQhp4v29wv @rcpsglasgow @Leeannemacklin

#CVCT2024: "There are many cardiology meetings around the globe-both in person and virtually. But CVCT stands out as this is the meeting that most comprehensively covers cardiovascular medicine across the spectrum. And what do I mean by spectrum? Spectrum of past knowledge with..

What’s new in #HF Oct 2024? https://t.co/eP6AuJovyH #Finerenone #FINEARTS-HF #FINE-HEART #Semaglutide #STEP-#HFpEF #SELECT #FLOW #MitraClip #RESHAPE-HF2 #MATTERHORN #Vutrisiran #HELIOS-B #Aficamten #SEQUOIA-#HCM #FOREST-HCM @PauCodi @DaniTomasoni_ @AlbertoAimo90 @ESC_Journals

#CVCT2024 : NEW ! Submit your abstract for POSTER PRESENTATIONS → A special French “Wine & Cheese Poster Viewing Session” will be organized just after the keynote lecture on the evening of December 10th, at the peak attendance of CVCT. Find out more here: https://t.co/5zu19JmLbt

@NHSResearchScot opportunities for associate PI apprenticeships! Can here more about it at the trainee meeting in Perth